CLEARSIDE BIOMEDICAL INC. - COMMON STOCK

Clearside Biomedical to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on Tuesday, March 12, 2024

29 Feb 2024 07:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical Announces Pricing of $15 Million Registered Direct Offering

07 Feb 2024 08:00:00 By Nasdaq GlobeNewswire

Clearside Biomedical Reports Significant Progress in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD

14 Dec 2023 07:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical Announces Third Quarter 2023 Financial Results and Provides Corporate Update

13 Nov 2023 16:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical to Participate in Fireside Chat at the Stifel 2023 Healthcare Conference

08 Nov 2023 07:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical’s Versatile Suprachoroidal Injection Platform Highlighted in Four Ophthalmic Indications in Clinical Data Presentations at AAO 2023 Annual Meeting

07 Nov 2023 16:20:00 By Nasdaq GlobeNewswire

Clearside Biomedical Announces Presentations at the American Academy of Ophthalmology 2023 Annual Meeting

02 Nov 2023 07:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical Completes Recruitment in ODYSSEY Phase 2b Clinical Trial of CLS-AX in Wet AMD

01 Nov 2023 07:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical to Report Third Quarter 2023 Financial Results and Provide Corporate Update on Monday, November 13, 2023

31 Oct 2023 07:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical Positive OASIS and Extension Study Data Presented at The Retina Society 56th Annual Scientific Meeting

16 Oct 2023 07:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical Announces Advancement of XIPERE® in Asia-Pacific for Suprachoroidal Treatment of Uveitic Macular Edema as Partner Arctic Vision Completes Enrollment in Phase 3 Clinical Trial in China

04 Oct 2023 09:00:00 By Nasdaq GlobeNewswire

Clearside Biomedical to Participate in a Panel Discussion at the JonesTrading 2023 Healthcare Summit

03 Oct 2023 16:35:00 By Nasdaq GlobeNewswire

Clearside Biomedical to Participate in Panel Discussion at the Cantor Global Healthcare Conference

19 Sep 2023 07:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical Announces Second Quarter 2023 Financial Results and Provides Corporate Update

14 Aug 2023 16:05:01 By Nasdaq GlobeNewswire

Clearside Biomedical to Participate in Upcoming Investor Conferences in August 2023

02 Aug 2023 16:30:00 By Nasdaq GlobeNewswire

Clearside Biomedical to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Monday, August 14, 2023

01 Aug 2023 07:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical Highlights Excellent Safety Profile of CLS-AX and Potential for Extended Duration of Effect in Data Presentation at the American Society of Retina Specialists 41st Annual Scientific Meeting

31 Jul 2023 07:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical’s Suprachoroidal Injection Platform to be Featured at Upcoming ASRS and OIS Scientific Meetings

20 Jul 2023 07:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical Announces Enrollment of Multiple Participants in its ODYSSEY Phase 2b Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMD

17 Jul 2023 07:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical CEO George Lasezkay to Present at the SHARE™️ Series Investor Event on Monday, July 17, 2023

11 Jul 2023 16:05:00 By Nasdaq GlobeNewswire